GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Amoy Diagnostics Co Ltd (SZSE:300685) » Definitions » Cash Flow from Financing

Amoy Diagnostics Co (SZSE:300685) Cash Flow from Financing : ¥-11 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Amoy Diagnostics Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Amoy Diagnostics Co paid ¥0 Mil more to buy back shares than it received from issuing new shares. It spent ¥1 Mil paying down its debt. It paid ¥0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent ¥1 Mil paying cash dividends to shareholders. It spent ¥5 Mil on other financial activities. In all, Amoy Diagnostics Co spent ¥6 Mil on financial activities for the three months ended in Mar. 2024.


Amoy Diagnostics Co Cash Flow from Financing Historical Data

The historical data trend for Amoy Diagnostics Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amoy Diagnostics Co Cash Flow from Financing Chart

Amoy Diagnostics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.39 -17.57 -46.32 -120.58 -18.04

Amoy Diagnostics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.39 -58.45 -1.34 55.14 -6.27

Amoy Diagnostics Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Amoy Diagnostics Co's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Amoy Diagnostics Co's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amoy Diagnostics Co  (SZSE:300685) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Amoy Diagnostics Co's issuance of stock for the three months ended in Mar. 2024 was ¥0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Amoy Diagnostics Co's repurchase of stock for the three months ended in Mar. 2024 was ¥0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Amoy Diagnostics Co's net issuance of debt for the three months ended in Mar. 2024 was ¥-1 Mil. Amoy Diagnostics Co spent ¥1 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Amoy Diagnostics Co's net issuance of preferred for the three months ended in Mar. 2024 was ¥0 Mil. Amoy Diagnostics Co paid ¥0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Amoy Diagnostics Co's cash flow for dividends for the three months ended in Mar. 2024 was ¥-1 Mil. Amoy Diagnostics Co spent ¥1 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Amoy Diagnostics Co's other financing for the three months ended in Mar. 2024 was ¥-5 Mil. Amoy Diagnostics Co spent ¥5 Mil on other financial activities.


Amoy Diagnostics Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Amoy Diagnostics Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Amoy Diagnostics Co (SZSE:300685) Business Description

Traded in Other Exchanges
N/A
Address
39 Dingshan Road, Haicang District, Xiamen, CHN, 361027
Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.
Executives
Ruan Li Directors, executives
Zheng Hui Bin Directors, executives
Chen Ying Directors, executives
Luo Jie Min Executives
Zhu Guan Shan Directors, executives
Yang Shou Qian Securities Affairs Representative
Zhou Wen Gang Executives
Zhou Xue Lin Independent director
Hu Xu Bo Director

Amoy Diagnostics Co (SZSE:300685) Headlines

No Headlines